

Special Issue

Non-invasive Biomarkers in Biologic Therapy for Oncology and Chronic Inflammation

Message from the Guest Editor

There is a growing interest in finding accurate non-invasive biomarkers for the identification of patients who might benefit from biologic therapy. Although this therapy has dramatically changed clinical practice, its benefits are curbed by the heterogeneous response of patients. It is therefore of utmost importance to find markers that predict the patient response to biologic therapy. To achieve this aspect of personalized medicine, one major step forward may be finding non-invasive biomarkers in human fluids (blood, saliva, urine, pleural fluid, tears, etc.).

In this Special Issue, experts in the field of cancer and inflammation will describe the most recent approaches (liquid biopsy, high throughput omics, extracellular vesicles, functional assays, etc.) to find non-invasive biomarkers of response to biologic therapy. This will include research articles using different sources of samples to apply these approaches.

- immunotherapy
- personalized medicine
- prognosis markers

Guest Editor

Dr. Silvia Vidal

Department of Immunology, Institut de Recerca, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Deadline for manuscript submissions

closed (31 January 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/93702

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).